Back to Overview
Dr. Bernd Fabry
Bernd Fabry started his professional career as a lecturer of Organic Chemistry at the FH Jülich before changing to Henkel KGaA in 1986, where he became laboratory manager. In 1990, he began to work in the Patent Department and was Deputy Head of Department until 1999.
- Chemistry & Engineering 100%
- Life Science 25%
- Trademarks 75%
- Employee Inventors Law 100%
Languages
German, Englisch, Spanish, French, Dutch
Contact
+ 49 2166.398.4651
What more there is to say...
After completing a degree in Chemistry and obtaining a Ph.D. at the RWTH Aachen, Bernd Fabry started his professional career as a lecturer of Organic Chemistry at the FH Jülich before changing to Henkel KGaA in 1986, where he became laboratory manager. In 1990, he began to work in the Patent Department and was Deputy Head of Department until 1999. From 1999 to 2011 he has been Managing Director of Cognis IP Management GmbH with responsibility for IP rights, but also for licenses and regulatory affairs.
For a decade Bernd Fabry was lecturer of IP Management at Otto-Beisheim School of Management in Vallendar; he has authored numerous papers and books in the field of IP protection. He founded IP2 in 2006.
Bernd prefers to spend his limited leisure time together with his big family. Bernd is an enthusiastic amateur chef and the best friend of a good bottle of wine; his less calorie-rich hobbies include cycling, water sports and writing crime novels.
What moves me
ADLON STAYS EXCLUSIVELY WITH KEMPINSKY
The brand „Adlon“ remains exclusively reserved for the Berlin luxury hotel Adlon Kempinski. The first instance court of the European Union (EuG) in Luxembourg dismissed a complaint of the sanitary products manufacturer Kludi on Wednesday, which wanted to sell bathroom...
PATENT TROLLS SUCCESSFUL AGAINST APPLE
According to a recent decision of a US court in Texas, technology giant Apple has infringed five patents hold by Optis Wireless Technology and was sentenced in the first instance to pay damages of at least half a billion dollar. Apple has announced taking the decision...
DOES REMDESIVIR KNOCK OUT CORONA?
Currently, there are intensive reports on the active Remdesivir from the US pharmaceutical giant Gilead. Chemically, the substance is a 1′-cyano 4-aza-7,9-didesazaadenosine C analogue of adenosine: It is a monophosphoramidate prodrug that is converted by metabolism...
Back to Overview